Online inquiry

IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11057MR)

This product GTTS-WQ11057MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets EGFR&LGR5 gene. The antibody can be applied in Colorectal Cancer (CRC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001346897.2; NM_001277226.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956; 8549
UniProt ID Q504U8; O75473
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11057MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ9360MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA INCMGA-00012
GTTS-WQ11880MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MLN-0264
GTTS-WQ2209MR IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ALT-803
GTTS-WQ3242MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ARGX-113
GTTS-WQ9897MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA KB001-A
GTTS-WQ12990MR IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PEG sTNF-RI
GTTS-WQ7543MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GC-182
GTTS-WQ11878MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MLN-0264
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW